Biofrontera Inc. Posts Record Q4 2025 Revenue, Shifts to Profitability — Biofrontera Inc.

Event summary

Biofrontera Inc. reported Q4 2025 revenue of $17.1M, up 36% YoY, driven by strong Ameluz sales and pricing adjustments.
Gross margins expanded to 82.4% from 58.0% YoY due to a favorable earnout structure from the Biofrontera AG transaction.
The company achieved its first profitable quarter with $5.6M net income, contrasting with a $1.4M loss in Q4 2024.
Biofrontera completed the acquisition of U.S. assets from Biofrontera AG, reducing earnout payments from 25-35% to 12-15% of net sales.
The company divested its Xepi antibiotic cream to Pelthos Pharmaceuticals for up to $9M, including milestone payments.

The big picture

Biofrontera's strategic transaction with Biofrontera AG has materially improved its cost structure, positioning it as the sole U.S. player advancing FDA-controlled PDT programs in dermatology. The company's shift to profitability and expanding clinical pipeline come amid a broader industry trend of consolidation and cost discipline in specialty dermatology. With patent protection extending to 2043, Biofrontera is poised to capitalize on its first-mover advantage in PDT, though execution risks remain.

What we're watching

Regulatory Milestones: The FDA's acceptance of the sNDA for Ameluz in sBCC sets a PDUFA date for September 2026, a key catalyst for revenue growth.
Pipeline Momentum: Positive Phase 3 results for Ameluz in AK and Phase 2b data in acne suggest expansion opportunities beyond current indications.
Cost Structure: The company's transition to a lower earnout structure and sustained profitability will be tested by its ability to maintain gross margins above 80%.